Loading...
•
Jun 30, 2021
Bausch Health Q2 2021 Earnings Report
Second quarter results demonstrated impressive overall company growth with strong performance and cash flow generation.
Key Takeaways
Bausch Health Companies Inc. announced its second-quarter 2021 financial results, demonstrating impressive overall company growth as businesses continue to recover from the COVID-19 pandemic. Total reported revenues were $2.100 billion, an increase of 26% compared to the second quarter of 2020. The company reported a GAAP net loss of $595 million and Adjusted EBITDA of $826 million.
Revenues of $2.100 Billion
GAAP Net Loss of $595 Million
Adjusted EBITDA (non-GAAP) of $826 Million
GAAP Cash Generated from Operations of $395 Million
Revenue by Segment
Forward Guidance
Bausch Health revised its revenue and Adjusted EBITDA (non-GAAP) guidance ranges for the full year of 2021, primarily due to the divestiture of Amoun Pharmaceutical Company S.A.E., the impact of a recall of certain Consumer products due to a quality issue at a third-party supplier and the negative impact of foreign exchange:
Positive Outlook
- Full-year revenue range of $8.40 – $8.60 billion
- Full-year Adjusted EBITDA (non-GAAP) range of $3.35 – $3.50 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...